A randomized controlled trial of ethyl glucuronide- based contingency management for outpatients with co-occurring alcohol use disorders and serious mental Illness

American Journal of Psychiatry

Volumn 174, Issue 4, 2017, Pages 370-377

  McDonell, Michael G ^a   Leickly, Emily ^a   McPherson, Sterling ^a   Skalisky, Jordan ^a   Srebnik, Debra ^a   Angelo, Frank ^a   Vilardaga, Roger ^a   Nepom, Jenny R ^a   Roll, John M ^a   Ries, Richard K ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; ETHYL GLUCURONIDE; GLUCURONIC ACID;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL INTOXICATION; ALCOHOLISM; ARTICLE; BIPOLAR DISORDER; BREATH ANALYSIS; CONTINGENCY MANAGEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MULTICENTER STUDY; OUTPATIENT; PATIENT ATTENDANCE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; SCHIZOPHRENIA; SELF REPORT; SMOKING; SUBSTANCE USE; URINALYSIS; AMBULATORY CARE; BLOOD; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; MENTAL DISORDERS; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; URINE;

ADULT; ALCOHOLISM; AMBULATORY CARE; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; FOLLOW-UP STUDIES; GLUCURONATES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT COMPLIANCE; TOKEN ECONOMY;

EID: 85016992951     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16050627     Document Type: Article

References (35)

1. Mokdad AH, Marks JS, Stroup DF, et al: Actual causes of death in the United States, 2000. JAMA 2004; 291:1238-1245
2. Bouchery EE, Harwood HJ, Sacks JJ, et al: Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 2011; 41:516-524
3. Cohen E, Feinn R, Arias A, et al: Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2007; 86:214-221
4. Buckley PF: Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry 2006; 67(Suppl 7):5-9
5. Lohr JB, Flynn K: Smoking and schizophrenia. Schizophr Res 1992; 8:93-102
6. DHHS: Substance Abuse Treatment for Persons with Co-occurring Disorders. A Treatment Improvement Protocol TIP 42. Rockville, Md, US DHHS, 2005
7. Bradizza CM, Stasiewicz PR, Dermen KH: Behavioral Interventions for Individuals Dually-Diagnosed with a Severe Mental Illness and a Substance Use Disorder. Curr Addict Rep 2014; 1:243-250
8. Hunt GE, Siegfried N, Morley K, et al: Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2013; 10:CD001088
9. Wakefield PA, Randall GE, Richards DA: Identifying barriers to mental health system improvements: an examination of community participation in assertive community treatment programs. Int J Ment Health Syst 2011; 5:27
10. BrunetteMF,Asher D, Whitley R, et al:Implementation of integrated dual disorders treatment: a qualitative analysis of facilitators and barriers. Psychiatr Serv 2008; 59:989-995
11. Benishek LA, Dugosh KL, Kirby KC, et al: Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction 2014; 109:1426-1436
12. Prendergast ML, Hall EA, Roll J, et al: Use of vouchers to reinforce abstinence and positive behaviors among clients in a drug court treatment program. J Subst Abuse Treat 2008; 35:125-136
13. Petry NM, Martin B, Cooney JL, et al: Give them prizes, and they will come: contingency management for treatment of alcohol dependence. J Consult Clin Psychol 2000; 68:250-257
14. Dougherty DM, Lake SL, Hill-Kapturczak N, et al: Using contingency management procedures to reduce at-risk drinking in heavy drinkers. Alcohol Clin Exp Res 2015; 39:743-751
15. Alessi SM, Petry NM: A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment. Addiction 2013; 108:900-909
16. Jatlow PI, Agro A, Wu R, et al: Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res 2014; 38:2056-2065
17. McDonell MG, Skalisky J, Leickly E, et al: Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug Alcohol Depend 2015; 157:184-187
18. Leickly E, McDonellMG, Vilardaga R, et al: High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-basedmass spectrometry.AmJ DrugAlcohol Abuse 2015; 41:246-250
19. McDonell MG, Howell DN, McPherson S, et al: Voucher-based reinforcement for alcohol abstinence using the ethyl-glucuronide alcohol biomarker. J Appl Behav Anal 2012; 45:161-165
20. Roll JM, Chermack ST, Chudzynski JE: Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: a feasibility study. Psychiatry Res 2004; 125:61-64
21. Bellack AS, Bennett ME, Gearon JS, et al: A randomized clinical trial of a new behavioral treatment for drug abuse in peoplewith severe and persistent mental illness. Arch Gen Psychiatry 2006; 63: 426-432
22. McDonell MG, Srebnik D, Angelo F, et al: Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatry 2013; 170:94-101
23. McDonell M, McPherson S, Vilardaga R, et al: Preliminary findings: Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults.AmJ Addict 2014; 23:407-410
24. Murphy SM, McDonell MG, McPherson S, et al: An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depend 2015; 153:293-299
25. Javors MA, Hatch JP, Lamb RJ: Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 2005; 100: 159-167
26. Sobell LC, Sobell MB: Alcohol timeline followback (TLFB), in Handbook of Psychiatric Measures. Washington, DC, American Psychiatric Publishing, 2000, pp 477-479
27. Donlin WD, Knealing TW, Needham M, et al: Attendance rates in a workplace predict subsequent outcome of employment-based reinforcement of cocaine abstinence in methadone patients. J Appl Behav Anal 2008; 41:499-516
28. Holtyn AF, Koffarnus MN, DeFulio A, et al: The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med 2014; 68:62-70
29. Petry NM, Peirce JM, Stitzer ML, et al: Effect of prize-based incentiveson outcomes instimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry 2005; 62:1148-1156
30. Zeger SL, Liang KY, Albert PS: Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-1060
31. Enders CK: Missing not at random models for latent growth curve analyses. Psychol Methods 2011; 16:1-16
32. Muthén B, Asparouhov T, Hunter AM, et al: Growth modeling with nonignorable dropout: alternative analyses of the STARD antidepressant trial. Psychol Methods 2011; 16:17-33
33. Schafer JL, Graham JW:Missing data: our view of the state of the art. Psychol Methods 2002; 7:147-177
34. Olmstead TA, Petry NM: The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine-or opioid-dependent outpatients. Drug Alcohol Depend 2009; 102:108-115
35. Sindelar J, Elbel B, Petry NM: What do we get for our money? Costeffectiveness of adding contingency management. Addiction 2007; 102:309-316